June 29, 2021

InterventionalMicromate400x275Austria’s Interventional Systems has announced that Micromate, a miniature medical robot for percutaneous procedures, has received FDA 510(k) clearance, allowing the robotics company to operate in the U.S. The company said it plans to launch operations throughout the second half of 2021 by launching centers of excellence for robotic-guided interventional procedures, and establishing commercial partnerships with third parties looking for a robot offering to their customers.

The Micromate is a table-mounted medical robot for interventional procedures with a universal instrument guidance solution that allows physicians to continue using their preferred surgical instruments. Targeting is performed under live-imaging using any Cone-Beam Computerized Tomography (CT), Fluoro CT or a Fluoroscope, the company said. 

“We appreciate the partnership developed with the FDA to rigorously validate safety and accuracy,” said Pedro Costa, the CPO of Interventional Systems. “It is not trivial to develop a full-fledged robotic platform that puts surgeons in charge of so many different procedures with the same core technology, while ensuring a seamless integration into the clinical workflow.”

Michael Vogele, the founder and CEO of Interventional Systems, said the company decided it was time to enter the U.S. following more than 10 years of experience in medical robots and a successful start with European partners. “We are sure our product is bound to democratize medical robots in the U.S.,” said Vogele. “The proven submillimeter accuracy and affordable price make it the most seasoned choice for any institution that is looking for new technology in order to improve the outcomes of interventional procedures.”

For more details on the company and the Micromate robot, visit the Interventional Systems website.

Related video: